Entropy Technologies LP Trims Stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Entropy Technologies LP cut its stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 4.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 6,829 shares of the biopharmaceutical company’s stock after selling 287 shares during the period. Entropy Technologies LP’s holdings in Intra-Cellular Therapies were worth $570,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Wilmington Savings Fund Society FSB raised its position in shares of Intra-Cellular Therapies by 55.7% in the 4th quarter. Wilmington Savings Fund Society FSB now owns 2,069 shares of the biopharmaceutical company’s stock worth $173,000 after acquiring an additional 740 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in Intra-Cellular Therapies by 10.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 22,480 shares of the biopharmaceutical company’s stock worth $1,878,000 after purchasing an additional 2,157 shares in the last quarter. R Squared Ltd bought a new position in Intra-Cellular Therapies in the fourth quarter worth $205,000. KBC Group NV lifted its position in Intra-Cellular Therapies by 31.8% during the fourth quarter. KBC Group NV now owns 3,774 shares of the biopharmaceutical company’s stock valued at $315,000 after buying an additional 910 shares during the period. Finally, SG Americas Securities LLC boosted its holdings in shares of Intra-Cellular Therapies by 204.4% during the 4th quarter. SG Americas Securities LLC now owns 12,917 shares of the biopharmaceutical company’s stock valued at $1,079,000 after buying an additional 8,673 shares in the last quarter. 92.33% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. Royal Bank of Canada reiterated a “sector perform” rating and issued a $132.00 price target (up from $108.00) on shares of Intra-Cellular Therapies in a research note on Wednesday, January 22nd. Needham & Company LLC reiterated a “hold” rating and set a $100.00 target price on shares of Intra-Cellular Therapies in a report on Monday, January 13th. StockNews.com started coverage on Intra-Cellular Therapies in a research report on Saturday. They issued a “hold” rating on the stock. Cantor Fitzgerald raised Intra-Cellular Therapies from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, January 14th. Finally, Baird R W downgraded Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Nine equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $103.62.

Intra-Cellular Therapies Stock Performance

ITCI opened at $127.56 on Wednesday. The company’s 50-day simple moving average is $102.37 and its two-hundred day simple moving average is $86.66. The stock has a market capitalization of $13.56 billion, a P/E ratio of -146.62 and a beta of 0.72. Intra-Cellular Therapies, Inc. has a 52-week low of $62.78 and a 52-week high of $128.00.

Insider Activity

In related news, CEO Sharon Mates sold 51,000 shares of Intra-Cellular Therapies stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $85.80, for a total value of $4,375,800.00. Following the completion of the sale, the chief executive officer now owns 1,070,329 shares of the company’s stock, valued at $91,834,228.20. The trade was a 4.55 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 2.60% of the stock is owned by corporate insiders.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.